Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F22%3A00133021" target="_blank" >RIV/00216224:14110/22:00133021 - isvavai.cz</a>
Result on the web
<a href="https://ashpublications.org/blood/article/140/Supplement%201/3258/490622/Single-Cycle-of-Blinatumomab-Followed-By-High-Dose" target="_blank" >https://ashpublications.org/blood/article/140/Supplement%201/3258/490622/Single-Cycle-of-Blinatumomab-Followed-By-High-Dose</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood-2022-157361" target="_blank" >10.1182/blood-2022-157361</a>

Result language
angličtina
Original language name
Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial
Original language description
Background: Blinatumomab induces a high proportion of complete molecular responses in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and ALL with persistent or recurrent measurable residual disease (MRD) after initial therapy. However, responses are generally short if they are not followed by allogeneic stem cell transplantation (HSCT). We infer that blinatumomab needs to be incorporated sequentially into the early phase of treatment to enhance rates of MRD negativity, lower the need of HSCT and improve survival.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)